Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01923740 · ClinicalTrials.gov registry record · NA
A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 480
- Enrollment target
NCT01923740 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 480 participants.
The verdict
NCT01923740, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 480 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.
Interventions
- DEVICE XIENCE V EECSS
- DEVICE Absorb BVS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-03-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01923740
The ClinicalTrials.gov registry entry for NCT01923740 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XIENCE V EECSS is the first listed.
NCT01923740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01923740 about?
NCT01923740 is a clinical study titled "A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)". To evaluate the safety and efficacy of the Absorb BVS System compared to the XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the treatment of subjects with ischemic heart disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels.
What is the current status of trial NCT01923740?
This trial is currently completed. It is a NA study. The enrollment target is 480 participants. The study started on 2013-07. Estimated completion is 2019-03-07.
What interventions are being tested in trial NCT01923740?
The interventions under investigation include: XIENCE V EECSS (DEVICE), Absorb BVS System (DEVICE).
Who is sponsoring clinical trial NCT01923740?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.